BR9810755A - Terapia de bloqueio de cd 154 para a sìndrome inibidora de proteìna terapêutica - Google Patents

Terapia de bloqueio de cd 154 para a sìndrome inibidora de proteìna terapêutica

Info

Publication number
BR9810755A
BR9810755A BR9810755-0A BR9810755A BR9810755A BR 9810755 A BR9810755 A BR 9810755A BR 9810755 A BR9810755 A BR 9810755A BR 9810755 A BR9810755 A BR 9810755A
Authority
BR
Brazil
Prior art keywords
therapeutic protein
blocking therapy
protein inhibitory
syndromes
attenuate
Prior art date
Application number
BR9810755-0A
Other languages
English (en)
Inventor
Burt Adelman
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9810755A publication Critical patent/BR9810755A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

Patente de Invenção: <B>"TERAPIA DE BLOQUEIO DE CD154 PARA A SìNDROME INIBIDORA DE PROTEìNA TERAPêUTICA"<D>. Métodos e composições para atenuar ou aliviar, suprimir, impedir, retardar o início ou reverter síndromes inibidoras de proteínas exógenas, exemplificadas pelas síndromes inibidoras de fatores coagulantes (por exemplo, o Fator VIII). Os métodos descritos usam um interruptor da ligação CD40:CD154, tal como um agente bloqueador de CD154, para atenuar ou aliviar a imunidade humoral bioinibitória contra-adaptativa direcionada contra uma proteína exógena de valor terapêutico.
BR9810755-0A 1997-06-20 1998-06-19 Terapia de bloqueio de cd 154 para a sìndrome inibidora de proteìna terapêutica BR9810755A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (1)

Publication Number Publication Date
BR9810755A true BR9810755A (pt) 2000-08-15

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810755-0A BR9810755A (pt) 1997-06-20 1998-06-19 Terapia de bloqueio de cd 154 para a sìndrome inibidora de proteìna terapêutica

Country Status (25)

Country Link
US (1) US20020119151A1 (pt)
EP (1) EP1034001B1 (pt)
JP (1) JP2002504910A (pt)
KR (1) KR100567998B1 (pt)
CN (2) CN1261285A (pt)
AT (1) ATE272408T1 (pt)
AU (1) AU733062B2 (pt)
BG (1) BG64436B1 (pt)
BR (1) BR9810755A (pt)
CA (1) CA2294138A1 (pt)
CZ (1) CZ295805B6 (pt)
DE (1) DE69825473T2 (pt)
EA (1) EA002512B1 (pt)
EE (1) EE9900587A (pt)
ES (1) ES2226152T3 (pt)
HK (1) HK1031825A1 (pt)
HU (1) HUP0002048A3 (pt)
IL (1) IL133305A0 (pt)
IS (1) IS2097B (pt)
NO (1) NO996274L (pt)
NZ (1) NZ502051A (pt)
PT (1) PT1034001E (pt)
SK (1) SK285962B6 (pt)
TR (1) TR199903141T2 (pt)
WO (1) WO1998058672A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01002898A (es) * 1998-09-21 2002-06-04 Genetics Inst Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
AU2004253868B2 (en) * 2003-06-13 2011-06-16 Biogen Ma Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
EP1694360B1 (en) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
WO2006017574A1 (en) * 2004-08-03 2006-02-16 Mayo Foundation For Medical Education And Research Improving treatments
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln

Also Published As

Publication number Publication date
EA200000059A1 (ru) 2000-08-28
EP1034001A1 (en) 2000-09-13
NZ502051A (en) 2001-04-27
KR20010013964A (ko) 2001-02-26
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
ES2226152T3 (es) 2005-03-16
CZ295805B6 (cs) 2005-11-16
IL133305A0 (en) 2001-04-30
CN1261285A (zh) 2000-07-26
US20020119151A1 (en) 2002-08-29
DE69825473T2 (de) 2005-08-04
CN1651071A (zh) 2005-08-10
IS2097B (is) 2006-04-12
PT1034001E (pt) 2004-12-31
ATE272408T1 (de) 2004-08-15
EP1034001B1 (en) 2004-08-04
SK180399A3 (en) 2000-06-12
HK1031825A1 (en) 2001-06-29
BG104092A (en) 2000-10-31
DE69825473D1 (de) 2004-09-09
AU8153698A (en) 1999-01-04
NO996274D0 (no) 1999-12-17
BG64436B1 (en) 2005-02-28
TR199903141T2 (xx) 2000-09-21
EA002512B1 (ru) 2002-06-27
IS5274A (is) 1999-11-26
HUP0002048A2 (hu) 2000-10-28
CA2294138A1 (en) 1998-12-30
AU733062B2 (en) 2001-05-03
JP2002504910A (ja) 2002-02-12
NO996274L (no) 2000-02-18
WO1998058672A1 (en) 1998-12-30
KR100567998B1 (ko) 2006-04-07
SK285962B6 (sk) 2007-12-06
CZ458899A3 (cs) 2000-04-12

Similar Documents

Publication Publication Date Title
BR9810755A (pt) Terapia de bloqueio de cd 154 para a sìndrome inibidora de proteìna terapêutica
WO2003053349A3 (en) Inhibitors of hepatitis c virus
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
MXPA04012965A (es) Inhibidores virales.
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
NO20053348L (no) Farmasoytisk sammensetning for behandling av virusangrep.
WO1996022305A3 (en) Modified peptides
WO2000041508A3 (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
WO2005016371A8 (en) IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES
NO991589L (no) Nye 3-,5- og/eller 6-substituerte analoger av swainsonin, fremgangsmÕter for deres fremstilling og deres anvendelse som terapeutiske midler
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
WO2003017920A3 (en) Protective factors against inflammation, burns and noxious stimuli
MXPA03006372A (es) Compuestos aromaticos simetricamente disustituidos y composiciones farmaceuticas para inhibir poli (adp-ribosa) glicohidrolasa y metodos para su uso.
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
MY141975A (en) Pyridyl substituted heterocycles useful for treating or preventing hcv infection

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA, INC. (US)

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37 DA LEI 9279/96, SUGIRO O INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O EM COMBINACAO COM O 13 E 24 DA LEI 9279/96.